

## Keensight Capital welcomes two Operating Partners

**Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout<sup>1</sup> investments, strengthens its team with the appointment of Dr. Edwin Moses and José Luis Martín as Operating Partners.**

**Edwin Moses'** appointment follows a very successful career as a biopharma entrepreneur, with decades of experience in building successful businesses. Among various achievements, he led the IPO for Ablynx and OAI (Oxford Asymmetry International), companies which he built and managed as CEO.

**José Luis Martín** was responsible for the development and implementation of corporate strategy at Werfen. For more than thirty years, he played a lead role in transforming the company from a local Spanish distributor to a large multinational company. The innovative firm is now a world leader in the In Vitro Diagnostics market with its products currently sold across more than 100 countries.

Edwin, based in Belgium, and José Luis, based in Spain, will be joining Keensight Capital's team of international Operating Partners. This network, spanning Europe, Asia and the US, connects eminent professionals in the Information Technology/Internet and Healthcare/Wellbeing industries. The Operating Partners share their extensive expertise, vision and international contacts with Keensight Capital's Investment and Portfolio Performance Teams. The domain-specific Board and Management experience they bring will enable Edwin and José Luis to play an active role in investment sourcing, and value creation for portfolio companies.

Pierre Remy, Managing Partner at Keensight Capital, said: *"Following the arrival of Christophe Lavigne in June, we are thrilled to welcome two seasoned professionals such as Dr. Edwin Moses and José Luis Martín in our outstanding network of Operating Partners. Their exceptional track record in expanding companies globally will benefit Keensight as well as the talented managers of our portfolio companies, notably in the Healthcare sector, one of our chosen fields."*



**Bio** – Dr. Edwin Moses was the former CEO of Ablynx, an innovative biopharma company acquired by Sanofi in 2018 for €3.9 billion. Prior to Ablynx, he was the CEO of OAI (Oxford Asymmetry International), a clinical research organization acquired by Evotec in 2000 for \$475 million. During his tenure as CEO of these two companies, which he built, Dr. Moses led their IPOs on the LSE, Euronext and NASDAQ and raised over €500 million in financing. He also secured biopharma licensing transactions with a potential value exceeding €10 billion.

A British national, Dr. Moses graduated from the University of Sheffield with a Bachelor and a Ph.D in chemistry.

---

<sup>1</sup> **Growth Buyout:** investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.



**Bio** – José Luis Martín is the former long-time CFO, Senior VP and Board Member of Werfen, a world leader in In Vitro Diagnostics, headquartered in Barcelona and present in 25 countries. During his time at Werfen, José Luis led key acquisitions that enabled the transformation of the company, from a local Spanish distributor to a multinational, innovative, leader in the industry. When he left the company, its annual revenues had reached more than €1.3 billion.

Originally from Spain, José Luis holds a Bachelor of Business Administration and a Master's in Business Administration and Management from the Escuela Superior de Administración y Dirección de Empresas (ESADE).

\* \* \*

#### **About Keensight Capital**

Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital's team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million.

Drawing on its expertise in the Information Technology/Internet and Healthcare/Wellbeing sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision.

[www.keensightcapital.com](http://www.keensightcapital.com)

#### **Media Contacts**

Anne de Bonnefon - [abonnefon@keensightcapital.com](mailto:abonnefon@keensightcapital.com) - +33 1 83 79 87 37

Citigate Dewe Rogerson

Alienor Miens – [alienor.miens@citigatedewerogerson.com](mailto:alienor.miens@citigatedewerogerson.com) - +33 6 64 32 81 75

Agathe Boggio – [agathe.boggio@citigatedewerogerson.com](mailto:agathe.boggio@citigatedewerogerson.com) - + 33 7 62 77 69 42